New Alzheimer’s drug disappoints in trials
Gantenerumab is part of a class of injected drugs designed to remove sticky protein pieces called beta amyloid from the brain. A buildup of those pieces is a hallmark of Alzheimer's. Roche, the company behind the drug, said it appeared to remove less of the protein pieces than expected.
Summary by Ground News
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Not enough coverage to generate an Article Assistant.
Ground News Article Assistant
Total News Sources0Leaning Left0Leaning Right0Center7Last Updated1 year agoBias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
To view ownership data please Upgrade to Vantage
Sources are mostly out of (0)